BioPorto A/S · OMXCOP:BIOPOR

BioPorto A/S — Shareholder Meeting (April 2017)

5 slides from BioPorto A/S's shareholder meeting presentation, Apr 21, 2017

  1. Slide 1: BioPorto General Meeting

    BioPorto General Meeting 21. April 2017

  2. Slide 2: Agenda

    AGENDA Report of the Company’s activities during the past year Presentation of the annual report for approval and allocation of profit or covering of loss Resolution to grant discharge of liability to the Board of Directors and Executive Management Approval of remuneration for the Board of Directors

  3. Slide 3: Headlines

    HEADLINES • Significant business potential – significant challenges • Challenges bring unique opportunities for learning and development • Management and key employees in BioPorto have handled the 2016 challenges impressively • … in spite of modest capital resources • Main challenges 2016 related to

  4. Slide 4: Headlines

    HEADLINES • Reasons for optimism regarding FDA approval in 2018 • Data from old clinical tests enabling adjustment of cut-off values to maximize sensitivity and specificity • New clinical trials designed with focus in areas where the old clinical trials provided strong results • BioPorto is being ba

  5. Slide 5: Headlines

    HEADLINES • Board Issues • New candidate: Kirsten Drejer • Extensive Life Science experience and a PhD in Pharmacology • Co-founder and CEO of Symphogen 2000-2016 • Novo Nordisk: Scientific and management positions • Proposal to increase remuneration for ordinary board members from DKK 150.000 to 25

BioPorto — Shareholder Meeting (April 2017) on 6ix